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Summary. Validamycin A has been successfully applied in the fight against phytopathogenic fungi. Here, the putative 
antifungal effect of this pseudooligosaccharide against the prevalent human pathogen Candida albicans was examined. 
Validamycin A acts as a potent competitive inhibitor of the cell-wall-linked acid trehalase (Atc1p). The estimated MIC50 for the 
C. albicans parental strain CEY.1 was 500 mg/l. The addition of doses below MIC50 to exponentially growing CEY.1 cells 
caused a slight reduction in cell growth. A concentration of 1 mg/ml was required to achieve a significant degree of cell killing. 
The compound was stable as evidenced by the increased reduction of cell growth with increasing incubation time. A homozygous 
atc1Δ/atc1Δ mutant lacking functional Atc1p activity showed greater resistance to the drug. The antifungal power of validamycin 
A was limited compared with the drastic lethal action caused by exposure to amphotericin B. The endogenous content of 
trehalose rose significantly upon validamycin and amphotericin B addition. Neither serum-induced hypha formation nor the 
level of myceliation recorded in macroscopic colonies were affected by exposure to validamycin A. Our results suggest that, 
although validamycin A cannot be considered a clinically useful antifungal against C. albicans, its mechanism of action and 
antifungal properties provide the basis for designing new, clinically interesting, antifungal-related compounds. [Int Microbiol 
2013; 16(4):217-225]
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Introduction
Substantial progress has been achieved in the last two decades 
in antifungal chemotherapy, which has been increasingly em-
ployed mainly because of the worldwide rise in the immuno-
compromised and aging human population [23] and the fre-
quent isolation in hospitals of classical non-pathogenic fungi 
responsible for nosocomial outbreaks [27,28]. These isolates 
mainly belong to the genera Aspergillus, Cryptococcus, and 
“non-albicans” species of Candida, although Candida albi-
cans remains the most prevalent infectious fungus in humans 
[8,9,24,27]. In recent years, the biggest problems associated 
with clinical fungal infections are related to the considerable 
increase in nosocomial bloodstream candidiasis, in which 
new factors of virulence [9], the rise of resistant fungal strains 
due to mutation, and the low selective toxicity of available 
antifungal therapies are characteristic [1,8,27]. This worrying 
scenario highlights the need for more secure and effective an-
tifungal therapies.
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In this context, considerable effort has been dedicated to 
improving conventional antimycotic drugs, e.g., the novel li-
posomal formulations of amphotericin B [15]. An alternative 
strategy requires the search for new cell targets combined 
with the screening of promising new antifungal compounds 
[23]. Our previous work supported both investigation into the 
enzymes involved in trehalose metabolism as potential anti-
fungal targets and clinical trials of inhibitors specifically de-
signed against trehalose-hydrolyzing enzymes [20,21,26]. 
Trehalose is a protective non-reducing disaccharide that is 
widely distributed in nature (bacteria, fungi, invertebrates, 
and plants) but absent in mammals. A loss of virulence is 
caused by the double disruption of the trehalose biosynthetic 
genes TPS1 and TPS2, and the corresponding tps1 and tps2 
null mutants show striking susceptibility to oxidative stress 
and heat shock. These observations are strong arguments in 
favor of therapeutically targeting the trehalose pathway 
[3,4,13,32]. Within this hydrolytic pathway, the ATC1 gene 
encodes the cell-wall-linked acid trehalase (Atc1p), required 
to cleave off exogenous trehalose; it is also involved in the 
induction of filamentation and virulence in C. albicans, and in 
improved resistance against different types of stress, such as 
heat shock or oxidative stress [25,26].
Structural analogues of trehalose from different biological 
sources (e.g., validamycin A, trehalosamine, trehazoline, no-
jirimycin, and calistegin) act as competitive or non-competi-
tive inhibitors of trehalase activity [10] and are therefore of 
interest for their putative antifungal activity. Notably, vali-
damycin A was introduced at the beginning of the 1980s in 
Japan and China to control rice sheath blight, caused by the 
phytopathogenic fungus Rhizoctonia solani [5]. It has also 
been tested against several ascomycetes and basidiomycetes 
[29]. Today, it is successfully used in crop protection as a her-
bicide and fungicide, since it is innocuous to human and ani-
mal health [17]. The structure of this secondary metabolite 
from Streptomyces hygroscopicus consists of an aminocycli-
tol moiety, validoxylamine A, linked to glucose through a 
β-glycosidic bond [7]. Validamycin A shows strong competi-
tive inhibition of several plant and insect trehalases, suggest-
ing its potential as an herbicide or insecticide [6,11,22]. To 
our knowledge, however, the antifungal action of validamycin 
A for clinical purposes against human fungal pathogens has 
never been examined, although the compound was tested in 
studies on the heat- and trehalose-associated control of mor-
phogenesis in C. albicans [31]. We therefore decided to inves-
tigate the putative antifungal action of validamycin A against 
Candida albicans, taking as our model the parental CEY.1 
(CAI-4-URA+) strain and its isogenic homozygous atc1Δ/
atc1Δ mutant (deficient in acid trehalase). Our results suggest 
that although validamycin A has a limited antifungal action 
against C. albicans, it does merit consideration as a basis for 
the design of new, alternative antifungal compounds.
Materials and methods
Yeast strains and culture conditions. Candida albicans strain 
CEY-1 (CAI-4-URA3+) (ura-3 Δ::imm-434/ura-3 Δ::im-434/ RP10::URA3) 
and the homozygous acid-trehalase-deficient mutant (atc1Δ/atc1Δ) 
(atc1Δ::hisG/atc1Δ::hisG-URA3-hisG-ura3Δ::imm434/ura3Δ::imm434) 
were used throughout this study. A detailed description of the constructions 
and procedures followed to obtain these strains is given elsewhere [26]. The 
cultures were grown at 37 °C (or 28 °C for experiments on dimorphic conver-
sion; see below) with shaking in a medium consisting of 2 % peptone, 1 % 
yeast extract, and 2 % glucose (YPD). The strains were maintained by peri-
odic subculturing in solid YPD medium. Growth was monitored by measur-
ing the OD600 of cultures in a Shimadzu UV spectrophotometer.
Sensitivity to validamycin A and amphotericin B. Validamycin 
was purchased from Duchefa Biochemie (Haarlem, The Netherlands) and 
two stock solutions were prepared by dissolving the compound in dimethyl 
sulfoxide at 100 mg/ml or 10 mg/ml (as the source for final doses of 1 mg/ml 
or 100 mg/ml validamycin A, respectively). The stock solutions were stored at 
–20 °C until use and diluted in sterile distilled water. Amphotericin B (Sigma, 
80 % purity) was prepared as indicated elsewhere [12]. Fungal cultures were 
grown in liquid YPD at 37 °C until the exponential phase (OD600 0.8–1.0) and 
were then divided into several aliquots, which were treated with the indicated 
doses of validamycin A or amphotericin B. After incubation for 24 h at 37 °C, 
viability was determined (see viability determination) and compared with a 
control without validamycin A. The concentration of validamycin A that in-
duced 50 % inhibition of growth (MIC50) was calculated.
Viability determination. Cultures were grown in liquid YPD overnight 
and then refreshed in the same medium until they reached the early exponen-
tial phase of growth (OD600 0.2–0.3). Then, the samples were divided into sev-
eral identical aliquots, which were treated with two different validamycin A 
concentrations, 0.1 and 1.0 mg/ml, chosen as a function of the MIC50, or main-
tained without treatment as a control; all cultures were incubated at 37 °C until 
an OD600 of 0.8–1.0. Viability was determined in samples diluted appropriately 
with sterile water, plated in triplicate on solid YPD, and then incubated for 2–3 
days at 37 °C. Between 30 and 300 colonies were counted per plate. Survival 
was normalized to that of the control samples (100 % viability).
Induction of germ tube formation. For germ-tube induction, sam-
ples were harvested at different stages of growth, rapidly washed with water, 
and resuspended at a density of 0.6–0.8 mg/ml (dry weight) in YPD pre-
warmed to 37 °C and containing 10 % (v/v) filter-sterilized (0.45 µm, Milli-
pore) human serum. Filamentation was also examined in colonies growing on 
Spider medium plates incubated at 37 °C for 7 days. The appearance of germ 
tubes was monitored using a phase-contrast light microscope equipped with a 
hemocytometer. When required, clumped cells were dispersed by mild soni-
cation (10–15 s) prior to microscopic examination. At least 250 cells were 
counted for each time-point and the percentage of dimorphism was defined as 
the ratio of germ-tube-forming cells to the total number of cells [2,26].
Preparation of cellular extracts. After exposure to validamycin A, 
samples from the cultures were harvested and resuspended at known densi-
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ties (10–15 mg/ml, wet weight) in N-morpholine ethanesulfonic acid (MES) 
extraction buffer (100 mM), pH 6.0, containing 5 mM cysteine and 0.1 mM 
phenylmethylsulfonyl fluoride. The cellular suspensions were transferred 
into small, pre-cooled tubes (0.5 cm diameter) containing Ballotini glass 
beads (0.45 mm diameter). The cells were broken by vibrating the tubes vig-
orously in a vortex mixer. The tubes were cooled quickly on ice, and the cell 
extracts were then centrifuged at 12,000 ×g for 10 min. The supernatant (cyto-
solic extract) and the pellet, resuspended in the same buffer (cell-wall ex-
tract), were preserved at 4 °C if used immediately or at –20 °C for further 
enzymatic analysis. The protein content in cellular extracts was estimated 
according to Lowry et al. [19], with bovine serum albumin as standard. 
Enzymatic assays. The acid trehalase assay was performed by incubat-
ing 50 μl of cell-wall extract with 200 μl of trehalose (200 mM) prepared in 
200 mM sodium citrate, pH 4.5, containing 2 mM EDTA. The reaction for 
neutral trehalase activity contained 50 μl of cytosolic extract (25–100 μg pro-
tein) and 200 μl of trehalose (200 mM) prepared in 25 mM MES, pH 7.1, and 
125 μM CaCl2. The reactions were incubated at 30 °C for 30 min and stopped 
by heating in a water bath at 95 °C for 5 min. The amount of glucose released 
was determined by the glucose oxidase-peroxidase method. The specific ac-
tivity is expressed as nmol glucose min–1 (mg protein)–1. Catalase activity was 
determined at 240 nm by monitoring the removal of H2O2, as described else-
where [12]. Specific activity is expressed as mmol min min−1 (mg protein)–1.
Determination of endogenous trehalose. Intracellular trehalose 
was measured according to a previously described method [26]. Briefly, cell 
samples (20–50 mg, wet weight) were washed, resuspended in 1 ml of water, 
and boiled for 30 min with occasional shaking. The concentration of trehalose 
released in the supernatant was determined with commercial trehalase (Sigma). 
The assay contained 90 μl of 25 mM sodium acetate buffer, pH 5.6, 100 μl of 
cell-free supernatant, and 10 μl of trehalase (2 units/ml). After incubation of 
the samples overnight at 37 °C, the amount of glucose produced was esti-
mated by the glucose oxidase-peroxidase procedure. Parallel controls were 
run to correct for basal glucose levels.
Morphological analysis. The morphology of the cells after the differ-
ent antifungal exposures was imaged with a Leica DM6000B microscope 
equipped with a Leica DFC280 camera connected to a PC and by using Leica 
Application Suite V 2.5.0 R1 software. Images were captured by bright field 
microscopy, using the 40× objective with an on-screen magnification of 
920×, and then processed and analyzed with the public domain software Im-
ageJ [http://rsb.info.nih.gov/ij/], a Java-based image processing program de-
veloped at the National Institute of Health.
Statistical analysis. Data are presented as mean ± SD. The data were 
analyzed by Duncan´s multiple test. The results shown are from three to five 
independent experiments.
Results
Effect of validamycin A on acid trehalase ac-
tivity (Atc1p) in Candida albicans. Validoxy lamine 
A, the aglycone fraction of validamycin A, behaves as a po-
tent and specific competitive inhibitor of the soluble trehalase 
present in the pathogenic fungus Rhizoctonia solani [5]. 
Therefore, we initially analyzed whether this inhibitory action 
of validamycin A was also operative against the acid trehalase 
of C. albicans, a cell-wall-linked enzyme involved in the hy-
drolysis of exogenous trehalose [25,26]. According to the 
Dixon plot shown in Fig. 1, in the parental C. albicans strain 
CEY.1 (CAI-4-URA+), validamycin A also inhibited this enzy-
matic activity in a competitive manner, with an apparent dis-
sociation constant (Ki) of about 1.5 µg/ml (3.02 × 10
–6 M). 
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Fig. 1. Dixon plot for validamycin A inhibition of acid trehalase activity in exponentially growing cells of the C. albicans CEY.1 (CAI-4-URA+) strain. The 
incubation mixtures contained the following concentrations of trehalose: 1 mM (closed circle), 10 mM (closed square), 25 mM (closed up triangle), and 100 mM 
(closed down triangle).
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This value was higher than the Ki recorded for validoxylamine 
A in R. solani [5,6], although the two cannot be strictly com-
pared because we used cell-wall extracts, rather than partially 
purified samples, as the enzymatic source. Furthermore, only 
acid trehalase activity can be measured in the crude homoge-
nates, as demonstrated by specific antibody binding [30], 
which excludes hypothetical residual cross-contamination 
with the cytosolic fraction containing neutral trehalase. 
Effect of validamycin A on cell growth and the 
viability of the CAI-4 and atc1∆ null strains of 
Candida albicans. In C. albicans, the lack of a functional 
URA3 gene affect the growth and virulence capacity of the 
fungus [16]. Therefore, in this study we used two URA3+ 
strains previously employed in studies on dimorphism and in-
fectivity [26]. To test the putative antifungal role of validamy-
cin A, we measured the response of parental CEY.1 cells to 
the addition of two concentrations of this inhibitor, chosen 
according to the corresponding MIC50 and calculated in ad-
vance (500 mg/l) as described in the Materials and methods 
section. Turbidimetric inspection (Fig. 2A) showed that 0.1 mg 
validamycin A/ml caused a slight decrease in cell growth while 
the reduction was more prominent in samples exposed to a con-
centration of 1000 mg/l (2× MIC50) (Fig. 2A). The determined 
cell viability (Fig. 2B) was consistent with the previously ob-
tained absorbance data (Fig. 2A). After 4 h of exposure, 0.1 mg 
validamycin A/ml caused a weak reduction in the number of 
viable cells compared with the control (Fig. 2B), and only the 
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Fig. 2. Effect of validamycin A (Val A) and amphotericin B (AmB) on the growth (as determined by turbidimetric analysis) and cell viability of the 
parental CAI-4-URA+strain (panels A and B, closed symbols) and the congenic mutant atc1Δ/atc1Δ (panels C and D, open symbols) of C. albicans. 
Cultures were grown at 37 °C in YPD liquid medium with shaking, in the absence (circles) or presence of validamycin A at concentrations of 0.1 
mg/ml (up triangle) and 1 mg/ml (down triangle) or amphotericin B at 0.5 μg/ml (square). Samples were harvested in duplicate at the indicated 
times for OD600 measurements in the CEY.1 (A) and atc1Δ/atc1Δ (C) strains. Cell viability was analyzed in CEY.1 (B) and atc1Δ/atc1Δ (D) strains 
subjected to the indicated treatments for 4 and 7 h. Identical, untreated samples were maintained at 37 °C as a control. The values shown are the 
mean ± SD of three independent measurements. The distinction between the values obtained for the treated samples and the controls was significant 
at *P < 0.05, **P < 0.01, and ***P < 0.001, according to Duncan’s multiple range test.
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highest concentration resulted in a significant level of cell 
death (ca. 50%). Prolonged incubation (7 h) in the presence of 
the compound produced only a slight additional increase in 
the fungicidal activity, which was dose-dependent (Fig. 2B). 
These results also suggested that validamycin A remained 
stable for long periods.  
We additionally analyzed the putative antifungal action of 
validamycin A on the homozygous null mutant atc1Δ/atc1Δ, 
which lacks a functional acid trehalase, the enzyme inhibited 
by the drug (Fig. 1). As expected, turbidimetric analysis re-
vealed that the mutant was more resistant to the inhibitory 
action of the drug than the parental strain (Fig. 2C). This re-
sistant phenotype was unequivocally confirmed through a 
count of viable cells in cultures incubated for 4 and 7 h in 
YPD liquid medium (Fig. 2D). Exposure to 1.0 mg validamy-
cin A/ml for 7 h resulted in a higher survival percentage of the 
mutant than of the parental cells (55 vs. 46 %, respectively) 
(Fig. 2B and 2D). Throughout this experimental work, the an-
tifungal action of validamycin was referred to that of ampho-
tericin B (0.5 mg/ml) in an identically treated sample, which 
was used as a positive control. The presence of the polyene 
provoked a dramatic amount of cell killing in both cell types 
(Fig. 2B and 2D). Taken together, our results suggest that 
validamycin A causes only a partial loss of cell viability and 
that, compared with other well-tested compounds currently 
available, it behaves as a weak antifungal agent.
By contrast, optical microscopy analysis of the yeast mor-
phology seemed to suggest a possible direct effect of the two 
tested antifungal agents (validamycin A and amphotericin B) 
in the reduction of individual cell size, which, in the case of 
validamycin A, was more noticeable after prolonged treat-
ment (Fig. 3). Thus, the results from five independent meas-
urements in exponential CEY.1 cultures showed a direct cor-
relation between the specific antifungal treatment applied for 
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Fig. 3. Morphological changes induced by validamycin A and amphotericin B in C. albicans strain CAI-4. YPD-grown CAI-4-URA+ cells (OD600 0.3) 
were treated with 0.1 mg validamycin A/ml or 0.5 μg amphotericin B/ml for 8 and 10 h. Identical, untreated samples were maintained at 37 °C as 
a control. 
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10 h and the subsequent cell size observed, the cell area of the 
control samples being larger than that of cells treated with 0.1 
mg validamycin A/ml (25.42 + 6.3 vs. 21.73 ± 4.8 mm2). As 
expected, the smallest cell sizes occurred in samples treated 
with 0.5 mg amphotericin B/ml (17.52 ± 2.8 mm2).
Changes in trehalose content during validamy-
cin A treatment. In C. albicans, the non-reducing disac-
charide trehalose acts as a specific protectant against oxida-
tive stress [3] and is also synthesized in response to ampho-
tericin B exposure [12]. Because the addition of validamycin 
A to several plant species triggers the rapid synthesis of the 
trehalose required to confront abiotic stresses [11,18,22], we 
measured the content of stored trehalose in CEY.1 and atc1Δ 
null cells under our experimental conditions. As shown in 
Table 1, endogenous disaccharide accumulation was greatest 
in the samples exposed to a concentration of validamycin A 
(100 mg/l) lower than its MIC50, whereas a 10-fold increase in 
the validamycin A dose triggered lower trehalose storage, 
probably due, at least in part, to the moderate toxicity caused 
by acute exposure of the cells to the drug. The strong antifun-
gal effect of amphotericin B caused similar damage to cell 
viability over short periods of time (1 h), as previously ob-
served (Fig. 2B and 2D). Thus, taken as a whole, the residual 
population that survived the antifungal challenge synthesized 
trehalose de novo to a lesser extent [12]. Consistent with pre-
vious findings, in the congenic atc1Δ null cells the intracellu-
lar disaccharide content was slightly higher [26]. 
Table 1. Changes in endogenous trehalose storage measured in response to different concentrations of 
validamycin A in the C. albicans URA+ strains CAI-4 and the atc1Δ/atc1Δ mutant 
Treatment
Trehalosea
CAI-4 atc1Δ/atc1Δ
Control 5.9 ± 0.7 6.8 ± 0.9
Validamycin A (0.1 mg/ml) 13.8 ± 1.5c 15.3 ± 2.4c
Validamycin A (1 mg/ml) 7.3 ± 1.1 9.1 ± 1.3
Amphotericin B (0.5 µg/ml) 12.7 ± 2.1c 14.5 ± 2.2c
anmol trehalose/mg wet weight.
bP < 0.05,  cP < 0.01 and dP < 0.001, according to Duncan’s multiple range test. 
Cultures were grown at 37 °C in YPD, harvested (OD600= 0.3), and exposed to the test concentrations 
of validamycin A for 4 h and to amphotericin B for 1 h. Control samples were maintained at 37 °C. 
The results are the mean ± SD of three independent measurements.
 
Table 2. Levels of enzymatic activities
Treatment
URA+ strains CAI-4 atc1Δ (null mutant of C. albicans)
Atc1p
nmol glucose ·
(mg protein)–1
Ntc1p
nmol glucose ·
(mg protein)–1
Catalase
mmol min–1 ·
(mg protein)–1
Atc1p
nmol glucose · 
(mg protein)–1
Ntc1p
nmol glucose · 
(mg protein)–1
Catalase
mmol min–1·
(mg protein)–1
Control 2.3 ± 0.3
(1.0)
18.5 ± 1.9
 (1.0)
0.77 ± 0.05
(1.0)
<0.3 19.1 ± 1.8
(1.0)
1.2 ± 0.3
(1.0)
Validamycin A (0.1 mg/ml) 
for 4 h at 37 ºC
1.7 ± 0.5
(0.74)
12.9 ± 1.6 
(0.7)c
0.65 ± 0.07 
(0.84)
<0.3 16.9 ± 1.7
(0.88)a
0.95 ± 0.5
(0.79)
Amphotericin B (0.5 mg/ml) 
for 1 h at 37 ºC
2.7 ± 0.8
(1.17)
27.2 ± 2,5
(1.47)c
2.8 ± 0.92
(3.63)c
<0.3 29.5 ± 1.4
(1.54)c
4.3 ± 0.2
(3.6)c
Numbers in parentheses are the relative activity normalized in relation to the control for each parameter, with the control treatment taken as 1.0. The 
results are the mean ± SD of three independent measurements.
aP < 0.05, bP < 0.01, and cP < 0.001 according to Duncan’s multiple range test.
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Enzymatic activity of the two trehalases and 
catalase in validamycin-A-treated Candida albi-
cans. To complement these studies, we tested a number of 
enzymatic activities that may play an important role in pro-
tecting the cellular integrity of C. albicans exposed to antifun-
gal treatments [12,26], including in response to validamycin A 
exposure. In terms of possible changes in the enzymatic path-
way involved in trehalose hydrolysis, Atc1p activity showed a 
certain degree of competitive inhibition in CAI-4- URA+ cells 
treated with 0.1 mg validamycin A/ml (Table 2), although 
basal enzymatic levels were very low because the ATC1 gene 
is subjected to catabolic repression by glucose in YPD medium 
[25]. As expected, acid trehalase was virtually undetectable in 
the atc1Δ null mutant (Table 2). Cytosolic Ntc1p activity was 
also diminished in the presence of validamycin A in CEY.1 
cells and, albeit to a lesser extent, in the atc1Δ strain (Table 2). 
Conversely, amphotericin B caused an increase in this activi-
ty, probably because the cells obtained the energy necessary 
to withstand stress through trehalose degradation. These data 
also point to a possible inhibitory action of amphotericin B on 
this cytosolic neutral trehalase. 
The induction of catalase activity has also been cited as a com-
ponent of cellular defenses against antifungal exposure [12]. 
However, there were no significant differences in the activity of 
this antioxidant between control samples and validamycin-A-
treated cells in the two strains analyzed, with higher basal levels in 
the atc1Δ cells. This is consistent with the observation that the 
double disruption of ATC1 in C. albicans confers superior resis-
tance to various environmental stresses [25,26]. In turn, in expo-
nentially growing cultures of the studied strains subjected to am-
photericin B (0.5 mg/ml) there was a clear activation of catalase, 
which likely reflected the capacity of the polyene to induce oxida-
tive damage in C. albicans [12]. Therefore, this antioxidant activ-
ity seems to be a sensitive mechanism to withstand antifungal 
treatments that might seriously compromise cell integrity, but it 
does not appear to act against weak antifungal exposure. In addi-
tion, catalase activity was not induced after the addition of vali-
damycin A, at least at the doses used in this study.
Effect of validamycin A on germ-tube forma-
tion in Candida albicans. The addition of human se-
rum (10 %) to cultures of C. albicans and the simultaneous 
transfer of the cells from 28 to 37 °C is a rapid and reliable 
procedure to induce germ-tube formation in this fungus [2]. 
We therefore analyzed whether validamycin A exerted some 
influence on the serum-induced dimorphic transition of the 
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Fig. 4. Effect of validamycin A on germ-tube formation. (A) Percentage of germ-tube formation induced by human serum. Exponentially 
growing cultures of CEY.1 (circles) and atc1Δ/atc1Δ (triangles) strains were incubated in YPD medium at 28 °C in the presence (open symbols) 
or absence (closed symbols) of 0.1 mg validamycin A /ml. At time zero, they were supplemented with sterile human serum (10 %) and 
incubated at 37 °C. CAI-4 cells grown at 28 °C without serum were run in parallel (filled squares) as the control. Values are the average of two 
determinations. (B) Germ-tube formation induced in colonies growing on Spider medium. The colony morphologies of strain CAI-4-URA+ on 
solid Spider medium were analyzed after a 7-day incubation at 37 °C in the presence or absence of 0.1 mg validamycin A /ml. The upper panel 
shows a whole colony and the lower panel a detail of the border.
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atc1Δ null mutant compared with the isogenic parental CEY.1 
cells. As shown in Fig. 4, the addition of validamycin A (0.1 
mg/ml) did not induce any significant variation in the number 
or kinetics of human-serum-induced germ-tube formation 
(Fig. 4A). Furthermore, the level of filamentation in CEY.1 
colonies that developed on Spider medium was not modified 
upon the addition of the inhibitor (Fig. 4B). Hence, these data 
suggested that validamycin A did not exert any conspicuous 
influence on the yeast-to-hypha conversion of C. albicans. In-
terestingly, the percentage of germ-tube formation recorded 
after 4 h of induction was similar in CEY.1 and atc1Δ cells, 
although in the latter strain dimorphic conversion was initially 
slower (Fig. 4A). This behavior might have well been due to 
structural perturbations in the intact cell wall that occurred as 
a consequence of the double disruption of ATC1 [26].
Discussion
The analysis of commercially available validamycin A leads 
us to propose that this compound is a weak antifungal drug 
against the prevalent opportunistic pathogen C. albicans, as 
opposed to its customary application against the phytopatho-
genic fungus R. solani in China and Japan [5,6]. However, in 
both fungal species, validamycin A acts as a potent competi-
tive inhibitor of cell-wall-linked acid trehalase, Atc1p (Fig. 1, 
Table 2) [5]. Notably, this compound also caused a significant 
reduction in cytosolic neutral trehalase activity (Ntc1p) in 
C. albi cans (Table 2), although we do not presently regard 
Ntc1p inhibition as the main cause of the weak fungicidal ef-
fect recorded. This observation suggests that either validamy-
cin A per se or its aglycone fraction (validoxylamine A) is able 
to cross the cell wall and plasma membrane in order to inhibit 
cytosolic hydrolases, although more experiments on specific 
transport are required to confirm this hypothesis. 
When provided in concentrations lower than the MIC50 
(100 mg/l), the drug had less effect on the viability of the 
CEY.1 strain of C. albicans, while cell damage was virtually 
negligible in an atc1Δ/atc1Δ mutant lacking functional Atc1p 
activity. An evident, but still partial, reduction in the level of 
survival required an increase in the dose of validamycin A to 
two-fold the MIC50, but this was still only achieved in the pa-
rental cells. As expected, atc1Δ null cells were less sensitive 
to the drug. The usefulness of validamycin A as a clinical an-
tifungal was thus clearly restricted compared with the impor-
tant amount of cell killing recorded in assays performed with 
the classical polyene amphotericin B, at least with respect to 
C. albicans as a pathogenic yeast model (Fig. 2).
In addition, validamycin A appeared to play no significant 
role in the induction of an intracellular antioxidant state pro-
moted by catalase activity (Table 2), which might be relevant 
for counteracting drastic antifungal exposure [12,15]. Fur-
thermore, the content of endogenous trehalose increased after 
the addition of 0.1 mg validamycin A/ml (Table 1), in agree-
ment with similar results obtained in distinct genetic back-
grounds of C. albicans [31]. However, the degree of accumu-
lation was lower in the presence of higher doses and after 
amphotericin B addition, probably because of the toxic effect 
provoked by these antifungal treatments (Table 1), whereas 
there was a slight decrease in antioxidant catalase activity in 
the presence of validamycin A (Table 2). Of note is the fact 
that ATC1, which encodes the acid trehalase activity, is not 
essential in C. albicans. However, it is clearly involved in 
virulence, since both heterozygous and homozygous mutants 
have a lower infectivity, as shown in a mouse model [25,26]. 
Thus, ATC1 is a potential target in the search for and design of 
new antifungals, although the specific inhibition of Atc1p by 
validamycin A only caused a partial reduction in cell viability 
and failed to affect the formation of hyphal structures (Figs. 2 
and 4).
Changes in the morphological and physical properties of 
fungal cells (shape, size, height, roughness or stiffness) are 
among the less well known toxic effects caused by the action 
of several antifungals, but they have been clearly demonstrat-
ed for amphotericin B and 5-flucytosine [14]. In our case, the 
addition of non-lethal doses of validamycin A caused a small 
but consistent diminution in cell size with respect to a control 
sample (Fig. 3). This effect on cell size was obviously depen-
dent on the antifungal power of the compound used; hence, a 
greater reduction was achieved in cells treated with ampho-
tericin B (Fig. 3). In turn, neither the percentage of serum-in-
duced germ-tube formation by blastospores nor the filamenta-
tion recorded in macroscopic colonies grown on Spider me-
dium was modified by exposure to validamycin A (Fig. 4). On 
the other hand, although trehalose hydrolysis does not seem to 
be a preferential energy source for serum-induced morpho-
genesis in C. albicans [2], recent evidence collated from a 
mutant deficient in the glucose sensing receptor Gpr1 indi-
cated that trehalose acts as negative regulator of filamentous 
development by counteracting the inhibitory effect of the 
HSP90 protein [31].
Thus, we conclude that, although validamycin A cannot 
presently be considered as a suitable clinical antifungal, it is 
likely to be a promising substrate in the design of new com-
pounds directed against the trehalose metabolism pathway as 
an antifungal target. This potential should promote future re-
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search into the development and testing of new drugs to more 
effectively combat life-threatening systemic infections caused 
by C. albicans.
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